期刊文献+

利用激光显微切割联合质谱蛋白质组学方法进行系统性淀粉样变性分型 被引量:14

Classification of amyloidosis by laser micro-dissection and mass spectrometry based proteomic analysis
原文传递
导出
摘要 目的 评估利用激光显微切割联合质谱蛋白质组学技术对系统性淀粉样变性进行分型的有效性.方法 以138例病理确诊为淀粉样变性患者的经福尔马林固定石蜡包埋标本为研究对象.利用显微切割收集刚果红染色阳性区域组织并行质谱蛋白质组学分析,以指数修正的蛋白质丰度指标(emPAI)为标准,根据丰度最高的致淀粉样变蛋白判定淀粉样变性亚型.结果 在138份组织标本中,腹壁脂肪占26%,舌体占19%,齿龈占11%,肾脏占9%,胃肠道占9%,心脏占6%,其余类型样本占20%.总共121例患者获得成功分型,包括轻链型106例(87.6%),遗传性甲状腺转运球蛋白型7例(5.8%),致淀粉样变蛋白A型、重链/重链+轻链型及纤维蛋白原α链型各2例(1.7%),载脂蛋白A-Ⅱ型及溶菌酶型各1例(0.8%).5例被排除淀粉样变性诊断,12例分型失败.总体诊断准确率为91.3%.在各种组织类型标本中,腹壁脂肪组织的分型成功率最低,仅为83.3%.结论 激光显微切割联合质谱蛋白质组学方法能有效鉴定出淀粉样变性亚型. Objectives To establish a novel method to determine specific type of amyloidosis through laser microdissection and mass spectrometry (LMD/MS) based proteomic analysis.Methods There were 138 formalin-fixed and paraffin-embedded (FFPE) biopsy samples of patients who were diagnosed as systemic amyloidosis used in this study.For each case,a 10 μm section stained with congored and positive amyloid deposits were identified under fluorescent light,followed by micro-dissection and mass spectrometry analysis.The amyloidosis subtype was confirmed based on the most abundant amyloid protein.Results The tissue types of 138 specimens were as following:subcutaneous abdominal fat accounted for 26%,tongue for 19%,gingiva for 11%,kidney for 9%,intestine for 9%,heart for 6% and others for 20%.Specific types of amyloid were accurately detected in 121 cases,including 106 (87.6%) amyloid light chain (AL) type,7 (5.8%) amyloid trans-thy-retin (ATTR),2 (1.7%) amyloidogenic protein A (AA),2 (1.7%) amyloid heavy chain (AH)/AL+AH,2 (1.7%) fibrinogen alpha chain (AFib),1 (0.8%) amyloid apolipoprotein A-type Ⅱ (AApoA-Ⅱ) and one (0.8%) amyloid lysozyme (ALys).Diagnosis of amyloidosis was excluded in 5 cases.The types of twelve cases were indeterminate by LMD/MS.On the whole,LMD/MS reached 91.3% accuracy rate in amyloid typing.Commonly involved organs (for example,heart,kidney and liver) turned out to be suitable sources of FFPE samples with typing success rate of almost 100%.In contrast,MS analysis was successful in only 83.3% of subcutaneous abdominal fat samples.Conclusions LMD/MS method provided a more direct technique for accurate typing of amyloidosis in a single procedure.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2015年第2期99-102,共4页 Chinese Journal of Hematology
基金 国家自然科学基金(81370672) 首都临床应用特色研究(Z131107002213050)
关键词 淀粉样变性 显微切割 质谱分析法 蛋白质组学 Amyloidosis Microdissection Mass spectrometry Proteomics
  • 相关文献

参考文献15

  • 1Merlini G, Bellotti V. Molecular mechanisms of amyloidosis [J]. N Engl J Med, 2003, 349(6):583-596.
  • 2Sipe JD, Benson MD, BuxbaumJN, et al. Amyloid fibril proteinnomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis [J]. Amyloid, 2010, 17(3-4):101-104.
  • 3Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options [J]. J Clin Oncol, 2011, 29 (14): 1924-1933.
  • 4Vrana JA, Gamez JD, Madden B J, et al. Classification of amyloi- dosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens [J]. Blood, 2009, 114(24):4957-4959.
  • 5Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue [J]. Arch Neurol, 2011, 68(2): 195-199.
  • 6Arike L, Peil L. Spectral counting label-free proteomics [J]. Methods Mol Biol, 2014, 1156:213-222.
  • 7Lavatelli F, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses [J]. Amyloid, 2011, 18 (4) : 177-182.
  • 8Brambilla F, Lavatelli F, Merlini G, et al. Clinical proteomics for diagnosis and typing of systemic amyloidoses [J]. Proteomics Clin Appl, 2013, 7 ( 1-2 ) : 136-143.
  • 9孙维绎,李剑.淀粉样变性分型的研究进展[J].中国实验血液学杂志,2014,22(1):259-262. 被引量:12
  • 10Mollee P, Renaut P, Gottlieb D, et al. How to diagnose amyloido- sis[J]. Intern Med J, 2014, 44( 1 ):7-17.

二级参考文献30

  • 1Lachmann HJ,Booth DR,Booth SE. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis[J].N Engl J Met,2002,(23):1786-1791.
  • 2Lavatelli F,Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses[J].{H}AMYLOID-INTERNATIONAL Journal OF EXPERIMENTAL AND CLINICAL INVESTIGATION,2011,(4):177-182.
  • 3Sipe JD,Benson MD,Buxbaum JN. Amyloid fibril protein nomenclature:2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis[J].{H}AMYLOID-INTERNATIONAL Journal OF EXPERIMENTAL AND CLINICAL INVESTIGATION,2012,(4):167-170.
  • 4Xing Y,Higuchi K. Amyloid fibril proteins[J].{H}Mechanisms of Ageing and Development,2002,(12):1625-1636.
  • 5Benson MD. Liver transplantation and transthyretin amyloidosis[J].{H}Muscle & Nerve,2013,(2):157-162.
  • 6Rosenzweig M,Giralt S,Landau H. Light-chain amyloidosis:SCT,novel agents and beyond[J].{H}Bone Marrow Transplantation,2013,(8):1022-1027.
  • 7Leung N,Nasr SH,Sethi S. How I treat amyloidosis:the importance of accurate diagnosis and amyloid typing[J].{H}Blood,2012,(16):3206-3213.
  • 8Cohen AD,Comenzo RL. Systemic light-chain amyloidosis:advances in diagnosis,prognosis,and therapy[J].Hematology Am Soc Hematol Educ Program,2010.287-294.
  • 9Picken MM. New insights into systemic amyloidosis:the importance of diagnosis of specific type[J].Curt Opin Nephrol Hypertens,2007,(3):196-203.
  • 10Satoskar AA,Burdge K,Cowden DJ. Typing of amyloidosis in renal biopsies:diagnostic pitfalls[J].{H}ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE,2007,(6):917-922.

共引文献11

同被引文献103

  • 1陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2009:919.
  • 2孟磊,丁文惠.心脏淀粉样变[J].中华老年心脑血管病杂志,2007,9(10):713-714. 被引量:1
  • 3Pepys MB. Amyloidosis[J]. Annu Rev Med, 2006,57:223-241.
  • 4Pickford HA, Swensen SJ, Utz JP. Thoracic cross-sectional imaging of amy- loidosis[J]. A JR Am J Roentgenol, 1997,168(2) :351-355.
  • 5Mahmood S,Palladini G,Sanchorawala V ,et al. Update on treatment of light chain amyloidosis[J]. Haematologica, 2014,99 (2) : 209-221.
  • 6Chu H,Zhao L,Zhang Z, et al. Clinical characteristics of amy|oidosis with isolated respiratory system involvement :a review of 13 cases[J]. Ann Tho- rac Med, 2012,7 ( 4 ) : 243-249.
  • 7CibeiraMT,SanchorawalaV,SeldinDC,et al.Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation:long-term results in a series of 421 patients [J].Blood,2011,118(16):4346-4352.doi:10.1182/blood-2011-01-330738.
  • 8Jimenez-ZepedaVH,FrankeN,ReeceDE,et al.Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis:experience of a single institution [J].Br J Haematol,2014,164(5):722-728.doi:10.1111/bjh.12673.
  • 9GertzMA.Immunoglobulin light chain amyloidosis:2014 update on diagnosis,prognosis,and treatment [J].Am J Hematol,2014,89(12):1132-1140.doi:10.1002/ajh.23828.
  • 10DispenzieriA,GertzMA,KyleRA,et al.Serum cardiac troponins and N-terminal pro-brain natriuretic peptide:a staging system for primary systemic amyloidosis [J].J Clin Oncol,2004,22(18):3751-3757.doi:10.1200/JCO.2004.03.029.

引证文献14

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部